Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.890
-0.200 (-4.89%)
At close: Apr 28, 2026, 4:00 PM EDT
3.914
+0.024 (0.62%)
After-hours: Apr 28, 2026, 4:22 PM EDT
Agenus Employees
Agenus had 81 employees as of December 31, 2025. The number of employees decreased by 235 or -74.37% compared to the previous year.
Employees
81
Change (1Y)
-235
Growth (1Y)
-74.37%
Revenue / Employee
$1,409,827
Profits / Employee
-$1,247
Market Cap
149.37M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Fate Therapeutics | 161 |
| Molecular Partners AG | 134 |
| Alps Group | 93 |
| Tenaya Therapeutics | 70 |
| TuHURA Biosciences | 22 |
| AN2 Therapeutics | 21 |
| Galectin Therapeutics | 9 |
AGEN News
- 7 days ago - Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 - Business Wire
- 7 days ago - Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs - Business Wire
- 11 days ago - Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer - Business Wire
- 25 days ago - Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 - Business Wire
- 27 days ago - Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer - Business Wire
- 4 weeks ago - Agenus Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access - Business Wire
- 6 weeks ago - Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer - Business Wire